CRXM SEC-arkiveringar - Gene Biotherapeutics, Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

772320

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Gene Biotherapeutics, Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

February 3, 2023	SC 13G/A	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. / Jemapete Christopher J Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
April 14, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Commission file number): 001-
March 30, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Commission file number): 001-33635 GENE BIOTHER
October 27, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33635 GENE
September 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33635 GENE BIOTH
September 3, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33635 GENE
August 9, 2021	8-K/A	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 Gene Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-007587 (State or other jurisdiction of incor
August 9, 2021	EX-16.1	Marcum LLP’s letter addressed to the U.S. Securities and Exchange Commission dated August 6, 2021. EXHIBIT 16.1 FORM 8-K ATTACHMENT - CHANGE OF ACCOUNTANTS? LETTER August 6, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Gene Biotherapeutics, Inc. under Item 4.01 of its Form 8- K dated August 6, 2021 We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree
August 5, 2021	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 Gene Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-007587 (State or other jurisdiction of incorporation) (Commissio
July 28, 2021	EX-99.1	GENE BIOTHERAPEUTICS ANNOUNCES DIRECTOR RETIREMENT FOLLOWING 16 YEARS OF DISTINGUISHED SERVICE Exhibit 99.1 Press / Investor Contact: Gene Biotherapeutics Inc. Tel: (858) 414.1477 Email: [email protected] GENE BIOTHERAPEUTICS ANNOUNCES DIRECTOR RETIREMENT FOLLOWING 16 YEARS OF DISTINGUISHED SERVICE SAN DIEGO, CA ? July 28, 2021 ? Gene Biotherapeutics Inc. (formerly Taxus Cardium Pharmaceuticals Group Inc./trading symbol: CRXM) today announced that Mr. Murray H. Hutchison, ag
July 28, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 Gene Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-007587 (State or other jurisdiction of incorporation) (Commission
April 28, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 AMENDMENT NO. 2 TO SCHEDULE 13D ON SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 GENE BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) (C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 AMENDMENT NO.
April 26, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2021 Gene Biotherapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other jurisdiction of incorporation) (Commissio
April 26, 2021	EX-99.1	GENE BIOTHERAPEUTICS PARTNERS WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO MANUFACTURE GENERX [Ad5FGF-4] PHASE 3 ANGIOGENIC GENE THERAPY PRODUCT CANDIDATE FOR REFRACTORY ANGINA Exhibit 99.1 GENE BIOTHERAPEUTICS PARTNERS WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO MANUFACTURE GENERX [Ad5FGF-4] PHASE 3 ANGIOGENIC GENE THERAPY PRODUCT CANDIDATE FOR REFRACTORY ANGINA SAN DIEGO, CA – April 26, 2021 - Gene Biotherapeutics Inc. (OTC: CRXM) announced today that it has entered into an agreement with FUJIFILM Diosynth Biotechnologies (“FDB”) to manufacture the Generx [Ad5FGF-4] angi
April 23, 2021	EX-4.1	Description of Securities of the registrant Exhibit 4.1 Description of the Registrant?s Securities The following descriptions of our common stock, our preferred stock and certain provisions of our certificate of incorporation and bylaws are summaries and are qualified by reference to the complete copies of our certificate of incorporation and bylaws with are exhibits to this report. Gene Therapeutics, Inc. has one class of securities regist
April 23, 2021	EX-21	Subsidiaries of the registrant EXHIBIT 21 SUBSIDIARIES Name of Subsidiary Jurisdiction of Organization Activation Therapeutics, Inc. Delaware Angionetics, Inc. Delaware
April 23, 2021	EX-10.5	Asset Purchase Agreement dated July 15, 2018 between Activation Therapeutics, Inc. and Olaregen Therapeutix, Inc. for the sale of Excellagen. Exhibit 10.5 ASSET PURCHASE AGREEMENT BY AND BETWEEN ACTIVATION THERAPEUTICS INC. as Seller, AND OLAREGEN THERAPEUTIX INC. as Buyer, Dated as of July 15, 2018 TABLE OF CONTENTS ARTICLE I PURCHASE AND SALE OF ASSETS 2 1.1 Purchase and Sale of Assets 2 1.2 Assumption of Liabilities & Reimbursement of Credit 3 1.3 Closing 3 1.4 Payment 3 1.5 Transfer Documents 3 1.6 Further Assurances 4 1.7 Transfer
April 23, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Commission file number): 001-33635 GENE BIO
March 18, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* GENE BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
March 1, 2021	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ___)* GENE BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
December 22, 2020	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Gene Biotherapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 876767104 (CUSIP Number) 12/21/2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
June 1, 2020	SC 13D	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. / Nostrum Pharmaceuticals, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 GENE BIOTHERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 86767104 1 (CUSIP Number) Carlton R. Asher, Jr., Esq. 110 East 59th Street, Suite 2200 New York, New York 10022 Phone: (212) 308-7171 (Name, Address and Tel
June 1, 2020	EX-99.A CHARTER	Joint Filing Agreement EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of Gene Biotherapeutics, Inc.
June 1, 2020	EX-99.A CHARTER	Securities Purchase Agreement, dated as of May 22, 2020, between Nostrum Pharmaceuticals, LLC and Sabby Healthcare Master Fund, Ltd. Exhibit B SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made and entered into, effective as of May 22, 2020 (the “Effective Date”), by and between sabby healthcare master fund, ltd.
May 28, 2020	EX-10.1	Preferred Stock Purchase Agreement dated May 22, 2020 between the registrant and Nostrum Pharmaceuticals LLC for the purchase of Series B Convertible Preferred Stock. Exhibit 10.1 PREFERRED STOCK PURCHASE AGREEMENT This Preferred Stock Purchase Agreement (this “Agreement”) is made as of May 22, 2020, by and among Gene Biotherapeutics, Inc. a Delaware corporation with its principal office at 11230 Sorrento Valley Road Suite #220, San Diego, CA 92122 (“CRXM” or the “Company”) and Nostrum Pharmaceuticals, LLC Delaware limited liability company with its principal o
May 28, 2020	EX-10.4	Amendment No. 1 to Distribution and License Agreement dated April 14, 2020 between Angionetics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd. Exhibit 10.4 FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENT The undersigned, Angionetics Inc., a Delaware corporation (“Angionetics”) and a wholly-owned subsidiary of Gene Biotherapeutics, Inc., and Shanxi Taxus Pharmaceuticals Co., Ltd., a China-based company (“Licensee”), desire to amend, as of April 14, 2020, the Distribution and License Agreement, dated as of April 10, 2020 (the “D&L Ag
May 28, 2020	EX-10.5	License and Patent Assignment Agreement dated April 10, 2020 between Activation Therapeutics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd. Exhibit 10.5 LICENSE AND PATENT ASSIGNMENT AGREEMENT This LICENSE AND PATENT ASSIGNMENT AGREEMENT (this “Agreement”) dated as of April 10, 2020 is made by Activation Therapeutics Inc., a Delaware corporation (“Activation”), on its own behalf and on behalf of its Affiliates and Shanxi Taxus Pharmaceuticals Co., Ltd., a company incorporated under the laws of the People’s Republic of China (“Shanxi”)
May 28, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 Gene Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-007587 (State or other jurisdiction of incorporation) (Commission
May 28, 2020	EX-99.1	GENE BIOTHERAPEUTICS SECURES INVESTMENT FROM NOSTRUM PHARMACEUTICALS, LLC Exhibit 99.1 Press / Investor Contact: Gene Biotherapeutics Inc. Tel: (858) 414.1477 Email: [email protected] GENE BIOTHERAPEUTICS SECURES INVESTMENT FROM NOSTRUM PHARMACEUTICALS, LLC SAN DIEGO, CA – May 28, 2020 – Gene Biotherapeutics Inc. (OTC:CRXM, formerly Taxus Cardium Pharmaceuticals Group Inc.) today announced that it has received a strategic investment from Nostrum Pharmaceuticals,
May 28, 2020	EX-10.2	Reaffirmation and Ratification Agreement dated April 10, 2020 between the registrant and Shanxi Taxus Pharmaceuticals Co. Ltd. Exhibit 10.2 REAFFIRMATION AND RATIFICATION AGREEMENT April 10, 2020 GENE BIOTHERAPEUTICS, iNC. 11568 Sorrento Valley Road Suite Fourteen San Diego, CA 92121 Ladies and Gentlemen: Shanxi Taxus Pharmaceuticals Co., Ltd. (“Shanxi”) executed and delivered to Gene Biotherapeutics, Inc. (“Company”) a Restructuring Plan Settlement Letter dated December 19, 2019 (“Letter Agreement”) pursuant to which Sha
May 28, 2020	EX-3.1	Certificate of Designation for Series B Convertible Preferred Stock Exhibit 3.1 GENE BIOtherapeutics, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Christopher J. Reinhard and Lois Chandler, do hereby certify that: 1. They are the President and Secretary, respectively, of Gene Biotherapeutics, Inc., a Delaware corporatio
May 28, 2020	EX-10.3	Distribution and License Agreement Dated April 10, 2020 between Angionetics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd. Exhibit 10.3 DISTRIBUTION AND LICENSE AGREEMENT THIS DISTRIBUTION AND LICENSE AGREEMENT (“Agreement”) dated as of April 10, 2020, is entered into between Angionetics Inc., a Delaware corporation having its principal place of business at 11568 Sorrento Valley Rd., Suite 14, San Diego, CA 92121 (“Angionetics”), a wholly-owned subsidiary of Gene Biotherapeutics, Inc., and Shanxi Taxus Pharmaceuticals
March 20, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2019 Gene Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other jurisdiction of incorporation) (Comm
March 20, 2019	EX-99.1	GENE BIOTHERAPEUTICS ANNOUNCES DIRECTOR RETIREMENT FOLLOWING A DECADE OF DISTINGUISHED SERVICE Exhibit 99.1 Press / Investor Contact: Gene Biotherapeutics Inc. Tel: (858) 414.1477 Email: [email protected] GENE BIOTHERAPEUTICS ANNOUNCES DIRECTOR RETIREMENT FOLLOWING A DECADE OF DISTINGUISHED SERVICE SAN DIEGO, CA – March 20, 2019 – Gene Biotherapeutics Inc. (formerly Taxus Cardium Pharmaceuticals Group Inc./trading symbol: CRXM) today announced that Gerald J. Lewis (age 85) has retir
January 22, 2019	SC 13D	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. / Rothenburg Barry Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) GENE BIOTHERAPEUTICS INC. (FORMERLY TAXUS CARDIUM PHARMACEUTICALS GROUP INC.) (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 86767104 1 (CUSIP Number) Barry Rothenburg 71-32 Austin Street, Second Floor Forest Hills,
December 4, 2018	NT 10-Q	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: September 30, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
September 13, 2018	EX-99.1	GENE BIOTHERAPEUTICS ANNOUNCES SALE OF EXCELLAGEN TECHNOLOGY PLATFORM; RETAINS COMMERCIALIZATION RIGHTS FOR GREATER CHINA AND RUSSIAN FEDERATION Exhibit 99.1 Press / Investor Contact: Gene Biotherapeutics Inc. Tel: (858) 414.1477 Email: [email protected] GENE BIOTHERAPEUTICS ANNOUNCES SALE OF EXCELLAGEN TECHNOLOGY PLATFORM; RETAINS COMMERCIALIZATION RIGHTS FOR GREATER CHINA AND RUSSIAN FEDERATION SAN DIEGO, CA – SEPTEMBER 5, 2018 – Gene Biotherapeutics Inc. (formerly Taxus Cardium Pharmaceuticals Group Inc./trading symbol: CRXM) to
September 13, 2018	EX-99.2	Angionetics Generx Investor Presentations
September 13, 2018	8-K	Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2018 Gene Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other jurisdiction of incorporation) (
May 16, 2018	NT 10-Q	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. NT 10-Q OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response 2.
January 9, 2018	EX-99.1	TAXUS CARDIUM ANNOUNCES NAME CHANGE TO GENE BIOTHERAPEUTICS crxm-ex9916.htm Exhibit 99.1 Press / Investor Contact: Gene Biotherapeutics Inc. Tel: (858) 414.1477 Email: [email protected] TAXUS CARDIUM ANNOUNCES NAME CHANGE TO GENE BIOTHERAPEUTICS SAN DIEGO, CA ? January 8, 2018 ? Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Ge
January 9, 2018	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits crxm-8k20180109.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2018 Taxus Cardium Pharmaceuticals Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other
November 15, 2017	NT 10-Q	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. NT 10-Q crxm-nt10q20170930.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response 2.50 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2017 ? Transition Report
August 15, 2017	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10-Q crxm-nt10q20170630.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response 2.50 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2017 ? Transition Report on Fo
July 28, 2017	10-Q	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (E
July 28, 2017	10-K	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 001-33635 (Commission file number) TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation) (IRS Employer
July 28, 2017	EX-21.1	Subsidiaries of Taxus Cardium Pharmaceuticals Group Inc., a Delaware corporation Exhibit 21.1 Subsidiaries of Taxus Cardium Pharmaceuticals Group Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Angionetics Inc. (85% controlling interest) Delaware, USA Post-Hypothermia Corporation Delaware, USA Activation Therapeutics, Inc. Delaware, USA Life Again Insurance Solutions, Inc. Delaware, USA
May 16, 2017	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10-Q crxm-nt10q20170331.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response 2.50 SEC FILE NUMBER 001-33635 CUSIP NUMBER 876767104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Peri
March 30, 2017	NT 10-K	Taxus Cardium Pharmaceuticals Group NT 10-K crxm-nt10k20161231.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response 2.50 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2016 ? Transition Report o
March 21, 2017	10-Q	Taxus Cardium Pharmaceuticals Group 10-Q (Quarterly Report) crxm-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHAR
March 6, 2017	10-Q	Taxus Cardium Pharmaceuticals Group 10-Q (Quarterly Report) crxm-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACEU
March 1, 2017	10-Q	Taxus Cardium Pharmaceuticals Group 10-Q (Quarterly Report) crxm-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACE
January 10, 2017	8-K	Taxus Cardium Pharmaceuticals Group 8-K (Current Report/Significant Event) crxm-8k20170109.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2017 Taxus Cardium Pharmaceuticals Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other
January 10, 2017	EX-99.1	Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease crxm-ex9916.htm Exhibit 99.1 Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease SAN DIEGO, Jan. 9, 2017 /PRNewswire/ - An article titled "Heart Therapy," written by Gabor M. Rubanyi, M.D., Ph.D., co-founder of Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc
January 5, 2017	8-K	Taxus Cardium Pharmaceuticals Group 8-K (Current Report/Significant Event) crxm-8k20170104.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2017 Taxus Cardium Pharmaceuticals Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other
January 5, 2017	EX-99	Angionetics is a private, newly-formed, San Diego-based biotechnology company focused on the development of Generx® [alferminogene tadenovec], a phase 3 angiogenic gene therapy product candidate for the treatment of Myocardial Ischemia and Refractory crxm-ex9917.pptx.htm Angionetics is a private, newly-formed, San Diego-based biotechnology company focused on the development of Generx? [alferminogene tadenovec], a phase 3 angiogenic gene therapy product candidate for the treatment of Myocardial Ischemia and Refractory Angina, and other patients with Cardiac Syndrome X. USE OF INFORMATION This information is for the express use of the addressee.
January 4, 2017	8-K	Taxus Cardium Pharmaceuticals Group 8-K (Current Report/Significant Event) crxm-8k20170104.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2017 Taxus Cardium Pharmaceuticals Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other
January 4, 2017	EX-99.1	ANGIONETICS TO PRESENT AT TWO SAN FRANCISCO-BASED HEALTHCARE CONFERENCES: THE BIOTECH SHOWCASE 2017 AND THE 10TH ANNUAL ONEMED FORUM crxm-ex9916.htm Press / Investor Contact: Angionetics Inc. Tel: (858) 414.1477 Email: [email protected] ANGIONETICS TO PRESENT AT TWO SAN FRANCISCO-BASED HEALTHCARE CONFERENCES: THE BIOTECH SHOWCASE 2017 AND THE 10TH ANNUAL ONEMED FORUM SAN DIEGO, CA ? January 3, 2017? Angionetics Inc., a wholly-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), foc
December 29, 2016	10-K	Taxus Cardium Pharmaceuticals Group 10-K (Annual Report) crxm-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015 001-33635 (Commission file number) TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpo
December 29, 2016	EX-21.1	Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Exhibit 21.1 Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Angionetics Inc. Delaware, USA Post-Hypothermia Corporation Delaware, USA Activation Therapeutics, Inc. Delaware, USA Life Again Insurance Solutions, Inc. Delaware, USA
December 29, 2016	EX-10.22	FORM OF COMMON STOCK PURCHASE WARRANT TAXUS CARDIUM PHARMACEUTICALS GROUP Exhibit 10.22 FORM OF COMMON STOCK PURCHASE WARRANT TAXUS CARDIUM PHARMACEUTICALS GROUP Warrant Shares: Initial Exercise Date: , THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Ex
December 14, 2016	EX-99.1	TAXUS CARDIUM ANNOUNCES TWO DIRECTOR RETIREMENTS FOLLOWING A DECADE OF DISTINGUISHED SERVICE crxm-ex9916.htm Exhibit 99.1 Press / Investor Contact: Taxus Cardium Pharmaceuticals Group Inc. Tel: (858) 414.1477 Email: [email protected] TAXUS CARDIUM ANNOUNCES TWO DIRECTOR RETIREMENTS FOLLOWING A DECADE OF DISTINGUISHED SERVICE SAN DIEGO, CA – December 14, 2016 – Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced that Tyler Dylan-Hyde, Ph.D. and Mr
December 14, 2016	8-K	Taxus Cardium Pharmaceuticals Group 8-K (Current Report/Significant Event) crxm-8k20161214.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 14, 2016 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisd
November 15, 2016	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10-Q crxm-nt10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q
October 27, 2016	10-Q	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACEUTICALS GROUP INC
October 3, 2016	8-K	Taxus Cardium Pharmaceuticals Group 8-K (Current Report/Significant Event) crxm-8k20160928.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2016 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Juris
September 27, 2016	EX-10.1	EXCHANGE AND REDEMPTION AGREEMENT crxm-ex1016.htm Exhibit 10.1 EXCHANGE AND REDEMPTION AGREEMENT THIS EXCHANGE AND REDEMPTION AGREEMENT (the ?Agreement?), dated as of September 23, 2016, is entered into by and between Taxus Cardium Pharmaceuticals Group Inc., a Delaware Company (the ?Company?), and the party identified as ?Holder? on the signature page hereto (the ?Holder?). WHEREAS, pursuant to the Securities Purchase Agreement,
September 27, 2016	8-K	Taxus Cardium Pharmaceuticals Group 8-K (Current Report/Significant Event) crxm-8k20160927.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 23, 2016 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Juris
September 13, 2016	EX-99.1	ANGIONETICS’ GENERX® [Ad5FGF-4] GENE THERAPY BIOLOGIC RECEIVES FDA CLEARANCE FOR U.S. PHASE 3 CLINICAL STUDY AS A NEW, SINGLE DOSE, TREATMENT FOR CORONARY ARTERY DISEASE crxm-ex9916.htm Exhibit 99.1 Press / Investor Contact: Angionetics Inc. Tel: (858) 414.1477 Email: [email protected] ANGIONETICS? GENERX? [Ad5FGF-4] GENE THERAPY BIOLOGIC RECEIVES FDA CLEARANCE FOR U.S. PHASE 3 CLINICAL STUDY AS A NEW, SINGLE DOSE, TREATMENT FOR CORONARY ARTERY DISEASE SAN DIEGO, CA ? September, 12, 2016 ? Angionetics Inc., a majority-owned subsidiary of Taxus Cardi
September 13, 2016	8-K	Taxus Cardium Pharmaceuticals Group 8-K (Current Report/Significant Event) crxm-8k20160912.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 12, 2016 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Juris
August 29, 2016	10-Q	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Ex
August 29, 2016	10-Q	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Ex
August 16, 2016	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10-Q crxm-nt10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Tr
August 16, 2016	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10-Q crxm-nt10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Tr
July 11, 2016	EX-99.2	ANGIONETICS & A HUAPONT LIFE SCIENCES (CHINA) AFFILIATE ENTER INTO EQUITY FINANCING AGREEMENT FOR PHASE 3 CLINICAL DEVELOPMENT OF GENERX GENE THERAPY FOR ISCHEMIC HEART DISEASE EX-99.2 Exhibit 99.2 Press / Investor Contact: Angionetics Inc. Tel: (858) 414.1477 Email: [email protected] ANGIONETICS & A HUAPONT LIFE SCIENCES (CHINA) AFFILIATE ENTER INTO EQUITY FINANCING AGREEMENT FOR PHASE 3 CLINICAL DEVELOPMENT OF GENERX GENE THERAPY FOR ISCHEMIC HEART DISEASE SAN DIEGO, CA ? July 11, 2016 ? Angionetics Inc., a wholly-owned subsidiary of Taxus Cardium Pharma
July 11, 2016	EX-10.2	CONTRIBUTION AGREEMENT BETWEEN TAXUS CARDIUM PHARMACEUTICALS GROUP & ANGIONETICS INC. EX-10.2 Exhibit 10.2 CONTRIBUTION AGREEMENT BETWEEN TAXUS CARDIUM PHARMACEUTICALS GROUP & ANGIONETICS INC. This Contribution Agreement (the ?Agreement?), is made and entered into as of June 6, 2016, by and between Taxus Cardium Pharmaceuticals Group, Inc., a Delaware corporation (?Cardium?), and Angionetics, Inc., a Delaware corporation and a wholly owned subsidiary of Cardium (?Angionetics?) with
July 11, 2016	EX-10.1	Share Purchase Agreement dated June 7, 2016 among the registrant, Angionetics Inc. and Pineworld Capital Limited EX-10.1 Exhibit 10.1 EXECUTION VERSION SHARE PURCHASE AGREEMENT BY AND AMONG TAXUS CARDIUM PHARMACEUTICALS GROUP, INC., ANGIONETICS, INC. AND PINEWORLD CAPITAL LIMITED Dated as of June 7, 2016 EXECUTION VERSION TABLE OF CONTENTS Page SECTION 1 DEFINITIONS AND INTERPRETATIONS 1 1.1 Definitions 1 1.2 Certain Interpretations 5 SECTION 2 PURCHASE AND SALE OF THE SHARES; CLOSING DELIVERIES 6 2.1 Purcha
July 11, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2016 Taxus Cardium Pharmaceuticals Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other jurisdiction o
July 11, 2016	EX-99.1	CERTIFICATE OF DESIGNATION SERIES A CONVERTIBLE PREFERRED STOCK ANGIONETICS, INC. EX-99.1 Exhibit 99.1 CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF ANGIONETICS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Angionetics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the Corporation), in accordance with the provisions of Section 103 thereof, does hereby subm
July 11, 2016	EX-10.3	SERVICES AGREEMENT BETWEEN TAXUS CARDIUM PHARMACEUTICALS GROUP, INC & ANGIONETICS INC. EX-10.3 Exhibit 10.3 SERVICES AGREEMENT BETWEEN TAXUS CARDIUM PHARMACEUTICALS GROUP, INC & ANGIONETICS INC. This Services Agreement (?Agreement?) dated June 6, 2016 is made and entered into by and between Taxus Cardium Pharmaceuticals Group Inc., a Delaware corporation (?Cardium?), and Angionetics Inc., a Delaware corporation and a wholly owned subsidiary of Cardium (?Angionetics?), with respect t
July 11, 2016	EX-10.1	Distribution and License Agreement dated June 7, 2016 between Angionetics Inc. and Pineworld Capital Limited EX-10.1 Exhibit 10.1 DISTRIBUTION AND LICENSE AGREEMENT THIS DISTRIBUTION AND LICENSE AGREEMENT (?Agreement?) dated as of June 7, 2016 (?Effective Date?), is entered into between Angionetics Inc., a Delaware corporation having its principal place of business at 11750 Sorrento Valley Rd., Suite 250, San Diego, CA 92121 (?Angionetics?), a wholly-owned subsidiary of Taxus Cardium Pharmaceuticals, Inc
July 11, 2016	EX-99.1	ANGIONETICS & A HUAPONT LIFE SCIENCES AFFILIATE ENTER AGREEMENT TO COMMERCIALIZE GENERX® ANGIOGENIC GENE THERAPY PRODUCT CANDIDATE FOR ISCHEMIC HEART DISEASE IN CHINA EX-99.1 Exhibit 99.1 Press / Investor Contact: Angionetics Inc. Tel: (858) 414.1477 Email: [email protected] ANGIONETICS & A HUAPONT LIFE SCIENCES AFFILIATE ENTER AGREEMENT TO COMMERCIALIZE GENERX? ANGIOGENIC GENE THERAPY PRODUCT CANDIDATE FOR ISCHEMIC HEART DISEASE IN CHINA SAN DIEGO, CA ? July 11, 2016 ? Angionetics Inc., a wholly-owned subsidiary of Taxus Cardium Pharmaceuticals
July 11, 2016	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2016 Taxus Cardium Pharmaceuticals Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State or other jurisdiction o
May 16, 2016	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
March 31, 2016	NT 10-K	Taxus Cardium Pharmaceuticals Group NT 10-K NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
November 17, 2015	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition
August 17, 2015	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10Q NT 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Repor
July 23, 2015	EX-10.1	EXCHANGE AND REDEMPTION AGREEMENT EX-10.1 Exhibit 10.1 EXCHANGE AND REDEMPTION AGREEMENT THIS EXCHANGE AND REDEMPTION AGREEMENT (the ?Agreement?), dated as of July 22, 2015, is entered into by and between Taxus Cardium Pharmaceuticals Group Inc., a Delaware Company (the ?Company?), and the party identified as ?Holder? on the signature page hereto (the ?Holder?). WHEREAS, pursuant to the Securities Purchase Agreement, dated as of A
July 23, 2015	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 22, 2015 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incor
June 26, 2015	8-K	Current Report Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): June 26, 2015 001-33635 (Commission file number) TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of
June 18, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACEUTI
May 28, 2015	DEF 14A	Taxus Cardium Pharmaceuticals Group DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Pro
May 22, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 (Commission file number) TAXUS CARDIUM Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2014 001-33635 (Commission file number) TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporat
May 22, 2015	EX-21.1	Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Post-Hypothermia Corporation Delaware, USA Angionetics Inc. Delaware, USA Activation Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Post-Hypothermia Corporation Delaware, USA Angionetics Inc. Delaware, USA Activation Therapeutics, Inc. Delaware, USA To Go Brands, Inc. Delaware, USA Life Again Insurance Solutions, Inc. Delaware, USA
May 18, 2015	NT 10-Q	Taxus Cardium Pharmaceuticals Group NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Rep
April 13, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2015 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incor
April 13, 2015	EX-99.1	ANGIONETICS INITIAL EQUITY FUNDING TO ADVANCE AS INDEPENDENT COMPANY TO DEVELOP AND COMMERCIALIZE PHASE 3 GENERX® GENE THERAPY PRODUCT CANDIDATE EX-99.1 Exhibit 99.1 Press / Investor Contact: Taxus Cardium Pharmaceuticals Group Inc. Tel: (858) 414.1477 Email: [email protected] ANGIONETICS INITIAL EQUITY FUNDING TO ADVANCE AS INDEPENDENT COMPANY TO DEVELOP AND COMMERCIALIZE PHASE 3 GENERX® GENE THERAPY PRODUCT CANDIDATE SAN DIEGO, CA April 13, 2015 Taxus Cardium Pharmaceuticals Group Inc. (trading symbol: CRXM) today anno
April 9, 2015	EX-99.1	TAXUS CARDIUM ANNOUNCES AGREEMENT WITH DR. REDDY’S LABORATORIES TO CO-DEVELOP, MARKET & SELL GENERX ANGIOGENIC MICROVASCULAR GENE THERAPY IN CERTAIN INTERNATIONAL MARKETS EX-99.1 Exhibit 99.1 Press / Investor Contact: Taxus Cardium Pharmaceuticals Group Inc. Tel: (858) 414-1477 Email: [email protected] TAXUS CARDIUM ANNOUNCES AGREEMENT WITH DR. REDDYS LABORATORIES TO CO-DEVELOP, MARKET & SELL GENERX ANGIOGENIC MICROVASCULAR GENE THERAPY IN CERTAIN INTERNATIONAL MARKETS SAN DIEGO, CA April 7, 2015 Taxus Cardium Pharmaceuticals Group Inc. (trading
April 9, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 6, 2015 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incor
April 3, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2015 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incor
April 1, 2015	NT 10-K	Taxus Cardium Pharmaceuticals Group NT 10-K NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2014 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
January 15, 2015	EX-99.1	TAXUS CARDIUM ELECTS THREE NEW BOARD MEMBERS INCLUDING PRC STRATEGIC INVESTOR JIAYUE ZHANG, JOHN WALLACE U.S. EQUITY TRADING SERVICES EXECUTIVE AND WEI-WEI ZHANG INTERNATIONAL GENE THERAPY PIONEER EX-99.1 Exhibit 99.1 Press / Investor Contact: Taxus Cardium Pharmaceuticals Group Inc. Tel: (858) 436-1018 Email: [email protected] TAXUS CARDIUM ELECTS THREE NEW BOARD MEMBERS INCLUDING PRC STRATEGIC INVESTOR JIAYUE ZHANG, JOHN WALLACE U.S. EQUITY TRADING SERVICES EXECUTIVE AND WEI-WEI ZHANG INTERNATIONAL GENE THERAPY PIONEER SAN DIEGO, CA – January 15, 2015 – Taxus Cardium Pharma
January 15, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2015 Taxus Cardium Pharmaceuticals Group, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of In
January 8, 2015	SC 13D	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. / Shanxi Taxus Pharmaceuticals Co., Ltd. - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 TAXUS CARDIUM PHARMACEUTICALS GROUP INC.
November 19, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMAC
November 17, 2014	NT 10-Q	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. NT 10-Q - - NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
August 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACEUTIC
June 30, 2014	EX-99.1	CARDIUM ANNOUNCES POSITIVE INTERIM PHASE 3 CLINICAL DATA SHOWING SIGNIFICANT EFFICACY OF GENERX® ANGIOGENIC GENE THERAPY FOR MYOCARDIAL ISCHEMIA DUE TO CORONARY ARTERY DISEASE AT THE 2014 BIO INTERNATIONAL CONVENTION Pioneering Angiogenic Gene Therap EX-99.1 Exhibit 99.1 Press Contact: Rex Graham Corporate Communications (858) 232-2706 [email protected] CARDIUM ANNOUNCES POSITIVE INTERIM PHASE 3 CLINICAL DATA SHOWING SIGNIFICANT EFFICACY OF GENERX® ANGIOGENIC GENE THERAPY FOR MYOCARDIAL ISCHEMIA DUE TO CORONARY ARTERY DISEASE AT THE 2014 BIO INTERNATIONAL CONVENTION Pioneering Angiogenic Gene Therapy for the Potential Treatmen
June 30, 2014	8-K	Current Report FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): June 24, 2014 001-33635 (Commission file number) TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of
June 10, 2014	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): June 5, 2014 001-33635 (Commission file number) TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of
May 15, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 TAXUS CARDIUM PHARMACEUTI
May 15, 2014	EX-4.1	Form of Warrant Agreement issued to directors and officers in February 2014. Exhibit 4.1 COMMON STOCK PURCHASE WARRANT CARDIUM THERAPEUTICS, INC. Warrant Shares: Initial Exercise Date: February 28, 2014 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial Exerc
April 30, 2014	DEF 14A	- DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Pro
April 15, 2014	EX-21	Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Post-Hypothermia Corporation Delaware, USA Tissue Repair Company Delaware, USA To Go Brands, Inc. Delaw Exhibit 21.1 Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Post-Hypothermia Corporation Delaware, USA Tissue Repair Company Delaware, USA To Go Brands, Inc. Delaware, USA Life Again Insurance Solutions, Inc. Delaware, USA
April 15, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2013 (Commission file number) TAXUS CARDIUM Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2013 001-33635 (Commission file number) TAXUS CARDIUM PHARMACEUTICALS GROUP INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporat
April 1, 2014	NT 10-K	- FORM NT 10-K Form NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
March 18, 2014	EX-99.1	CARDIUM BECOMES TAXUS CARDIUM PHARMACEUTICALS GROUP IN CONNECTION WITH STRATEGIC COLLABORATION AND FUNDING WITH SHANXI TAXUS PHARMACEUTICALS EX-99.1 Exhibit 99.1 COMPANY CONTACTS Shareholder Services Taxus Cardium Pharmaceuticals Group Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM BECOMES TAXUS CARDIUM PHARMACEUTICALS GROUP IN CONNECTION WITH STRATEGIC COLLABORATION AND FUNDING WITH SHANXI TAXUS PHARMACEUTICALS SAN DIEGO, CA – March 17, 2014 – Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it
March 18, 2014	8-K	Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 14, 2014 Taxus Cardium Pharmaceuticals Group Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incor
March 18, 2014	EX-3.1	Certificate of Ownership and Merger of the registrant effective as of March 14, 2014 EX-3.1 Exhibit 3.1 CERTIFICATE OF OWNERSHIP AND MERGER MERGING TAXUS CARDIUM PHARMACEUTICALS GROUP INC. WITH AND INTO CARDIUM THERAPEUTICS, INC. Pursuant to Section 253 of the General Corporation Law of the State of Delaware Cardium Therapeutics, Inc., a Delaware corporation (the “Corporation”), does hereby certify to the following facts relating to the merger (the “Merger”) of Taxus Cardium Pharm
March 4, 2014	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2014 Cardium Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incorporation) (
March 4, 2014	EX-10.2	STOCK PURCHASE AGREEMENT EX-10.2 Exhibit 10.2 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is made and entered into as of February 21, 2014 (the “Effective Date”), by and between Cardium Therapeutics, Inc., a Delaware corporation (“Cardium” or the “Company”), and Shanxi Taxus Pharmaceuticals Co., Ltd., a limited liability company of the People’s Republic of China (“Taxus” or the “Purchaser”),
March 4, 2014	EX-99.1	CARDIUM ANNOUNCES STRATEGIC COLLABORATION AND FUNDING WITH TAXUS PHARMACEUTICALS TO SUPPORT COMMERCIAL DEVELOPMENT OF ADVANCED REGENERATIVE THERAPEUTICS EX-99.1 Exhibit 99.1 COMPANY CONTACTS Shareholder Services Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES STRATEGIC COLLABORATION AND FUNDING WITH TAXUS PHARMACEUTICALS TO SUPPORT COMMERCIAL DEVELOPMENT OF ADVANCED REGENERATIVE THERAPEUTICS SAN DIEGO, CA – March 3, 2014 – Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has
March 4, 2014	EX-10.1	11750 Sorrento Valley Rd., Suite 250, San Diego, CA 92121 • 858.436.1000 EX-10.1 Exhibit 10.1 February 21, 2014 Mr. Jiayue Zhang Chairman and President Shanxi Taxus Pharmaceuticals Co., Ltd. Houfangnan, Yutai Rd. Yuci District Jinzhong City, Shanxi Province China 030600 Re: Strategic Cooperation Between Cardium Therapeutics, Inc. and Shanxi Taxus Pharmaceuticals Co., Ltd. Dear Mr. Zhang: This letter is to confirm the terms of a strategic cooperation between Cardium The
January 13, 2014	25	- 25 25 OMB APPROVAL OMB Number: 3235-0080 Expires: December 31, 2014 Estimated average burden hours per response.
January 3, 2014	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 31, 2013 Cardium Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incorporation) (
January 3, 2014	EX-99.1	CARDIUM REPORTS ON ADVANCEMENT OF GENERX AND EXCELLAGEN BIOLOGIC PRODUCTS AND CORPORATE DEVELOPMENTS Clinical and Preclinical Results Have Implications for Use of Generx as a Non-Surgical Gene Therapy for Coronary Artery Disease, and Excellagen to Po EX-99.1 Exhibit 99.1 COMPANY CONTACT Shareholder Services Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM REPORTS ON ADVANCEMENT OF GENERX AND EXCELLAGEN BIOLOGIC PRODUCTS AND CORPORATE DEVELOPMENTS Clinical and Preclinical Results Have Implications for Use of Generx as a Non-Surgical Gene Therapy for Coronary Artery Disease, and Excellagen to Potenti
December 20, 2013	EX-99.1	CARDIUM PROVIDES UPDATE ON EXCHANGE LISTING EX-99.1 Exhibit 99.1 Investor Contact: Shareholder Services Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM PROVIDES UPDATE ON EXCHANGE LISTING SAN DIEGO, Calif. – December 20, 2013 - Cardium Therapeutics (NYSE MKT: CXM) today provided an update on its exchange listing. As previously reported, a communication from the staff of the company’s current li
December 20, 2013	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 18, 2013 Cardium Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incorporation) (
November 21, 2013	EX-10.1	ASSET ACQUISITION AGREEMENT To Go Brands, Inc. Cell-nique Corporation TABLE OF CONTENTS 1. ACQUISITION OF THE ASSETS 4 1.01. ACQUISITION OF THE ASSETS FROM THE TRANSFEROR 4 1.02. ASSUMPTION OF LIABILITIES FROM THE TRANSFEROR 4 1.03. CONSIDERATION FOR EX-10.1 Exhibit 10.1 ASSET ACQUISITION AGREEMENT Between To Go Brands, Inc. And Cell-nique Corporation TABLE OF CONTENTS 1. ACQUISITION OF THE ASSETS 4 1.01. ACQUISITION OF THE ASSETS FROM THE TRANSFEROR 4 1.02. ASSUMPTION OF LIABILITIES FROM THE TRANSFEROR 4 1.03. CONSIDERATION FOR THE ASSETS 5 1.04. CLOSING 5 1.05. TAX TREATMENT 5 2. REPRESENTATIONS OF THE TRANSFEROR REGARDING THE ASSETS AND ASS
November 21, 2013	8-K	Current Report Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): November 15, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpora
November 21, 2013	EX-99.1	CARDIUM’S TO GO BRANDS ACQUIRED BY CELL-NIQUE AND HEALTHY BRANDS COLLECTIVE EX-99.1 Exhibit 99.1 COMPANY CONTACTS Shareholder Services Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM’S TO GO BRANDS ACQUIRED BY CELL-NIQUE AND HEALTHY BRANDS COLLECTIVE SAN DIEGO, Calif. – November 18, 2013 - Cardium Therapeutics (NYSE MKT: CXM) today announced that Cell-nique Corporation, which owns a variety of innovative businesses that are p
November 19, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 CARDIUM THERAPEUTICS,
November 15, 2013	NT 10-Q	- NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2013 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
October 8, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): October 7, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporati
October 8, 2013	EX-99.1	CARDIUM PROVIDES UPDATE ON EXCHANGE LISTING EX-99.1 Exhibit 99.1 Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM PROVIDES UPDATE ON EXCHANGE LISTING SAN DIEGO, Calif. – October 7, 2013 – Cardium Therapeutics (NYSE MKT: CXM) today provided an update on its exchange listing. As previously reported, a communication from the staff of the
October 3, 2013	EX-99.1	UNUSUAL TRADING ACTIVITY IN CARDIUM COMMON STOCK EX-99.1 Exhibit 99.1 COMPANY CONTACT Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] UNUSUAL TRADING ACTIVITY IN CARDIUM COMMON STOCK SAN DIEGO, Calif. – September 27, 2013 - Cardium Therapeutics (NYSE MKT: CXM) today released the following statement. In view of the unusual market activity in the Company’s common st
October 3, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): September 27, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpor
September 17, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): September 16, 2013 CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State of incorporation) (Commission file n
September 17, 2013	EX-99.1	COMPANY CONTACTS Bonnie Ortega Liz Michel, JD VP – Corporate Communications Chief Marketing Officer Cardium Therapeutics, Inc. AgencyONE, LLC Tel: (858) 436-1018 Tel: (301) 803-7525 Email: [email protected] Email: [email protected] CAR EX-99.1 Exhibit 99.1 COMPANY CONTACTS Bonnie Ortega Liz Michel, JD VP – Corporate Communications Chief Marketing Officer Cardium Therapeutics, Inc. AgencyONE, LLC Tel: (858) 436-1018 Tel: (301) 803-7525 Email: [email protected] Email: [email protected] CARDIUM’S LIFEAGAIN LAUNCHES FIRST LIFE INSURANCE PROGRAM DEVELOPED FOR MEN WITH ACTIVE LOCALIZED PROSTATE CANCER SAN DIEGO, Calif.
August 28, 2013	EX-99.1	COMPANY CONTACTS Bonnie Ortega Liz Michel, JD VP – Corporate Communications Chief Marketing Officer Cardium Therapeutics, Inc. AgencyONE, LLC Tel: (858) 436-1018 Tel: (301) 803-7525 Email: [email protected] Email: [email protected] CAR EX-99.1 Exhibit 99.1 COMPANY CONTACTS Bonnie Ortega Liz Michel, JD VP – Corporate Communications Chief Marketing Officer Cardium Therapeutics, Inc. AgencyONE, LLC Tel: (858) 436-1018 Tel: (301) 803-7525 Email: [email protected] Email: [email protected] CARDIUM’S LIFEAGAIN ANNOUNCES COMMERCIALIZATION AGREEMENT WITH AGENCYONE BASED ON ADVANCED MEDICAL DATA ANALYTICS PLATFORM TECHNOLOG
August 28, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): August 26, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporati
August 16, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): August 7, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporatio
August 16, 2013	EX-99.1	Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARD EX-99.1 Exhibit 99.1 Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM ANNOUNCES EXCELLAGEN DISTRIBUTION AGREEMENT WITH KASIAK FOR GERMANY AND SWITZERLAND SAN DIEGO, CA – August 7, 2013 – Cardium
August 16, 2013	EX-99.3	CARDIUM REPORTS ON SECOND QUARTER 2013 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS EX-99.3 Exhibit 99.3 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM REPORTS ON SECOND QUARTER 2013 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS SAN DIEGO, CA – August 14, 2013—Cardium Therapeutics (NYSE MKT: CXM) today presented its financial results for the second quarter en
August 16, 2013	EX-99.2	Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARD EX-99.2 Exhibit 99.2 Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM REPORTS ON POTENTIAL USE OF EXCELLAGEN TO REPAIR PRENATALLY DIAGNOSED BIRTH DEFECTS USING MESENCHYMAL STEM CELLS SAN DIEGO, C
August 14, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 CARDIUM THERAPEUTICS, INC.
August 6, 2013	EX-99.3	Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARD EX-99.3 Exhibit 99.3 Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM REPORTS ON NEW EXCELLAGEN-BASED STROMAL CELL RESEARCH FOR WOUND HEALING WITH ORBSEN THERAPEUTICS UNDER EUROPEAN FP7 REDDSTAR
August 6, 2013	EX-99.1	Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARD EX-99.1 Exhibit 99.1 Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM REPORTS ON NEW EXCELLAGEN DISTRIBUTION AGREEMENT WITH AVKARE FOR VETERANS HOSPITALS AND OTHER GOVERNMENTAL MEDICAL FACILITIES
August 6, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): August 1, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporatio
August 6, 2013	EX-99.2	Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARD EX-99.2 Exhibit 99.2 Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM ANNOUNCES NEW EXCELLAGEN FDA 510(k) SUBMISSION BASED ON EXPANDED STRUCTURAL AND FUNCTIONAL PROPERTIES The Company Also Provid
July 19, 2013	EX-99.2	CARDIUM COMPLETES PREFERRED STOCK FINANCING EX-99.2 Exhibit 99.2 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM COMPLETES PREFERRED STOCK FINANCING SAN DIEGO, CA – July 19, 2013 - Cardium Therapeutics (NYSE MKT: CXM) today announced the completion of the second tranche of its previously described registered direct offering c
July 19, 2013	EX-99.1	CARDIUM ANNOUNCES REVERSE STOCK SPLIT EX-99.1 Exhibit 99.1 Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES REVERSE STOCK SPLIT SAN DIEGO, CA – July 18, 2013 - Cardium Therapeutics (NYSE MKT: CXM) announced a 1-for-20 reverse split of the Company’s issued and outstanding common stock effective at the open of the NYSE M
July 19, 2013	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 18, 2013 Cardium Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incorporation) (Comm
July 3, 2013	EX-99.1	CARDIUM ANNOUNCES FINAL VOTING RESULTS OF ANNUAL MEETING OF STOCKHOLDERS Company Also Provides Update on Exchange Listing EX-99.1 Exhibit 99.1 Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES FINAL VOTING RESULTS OF ANNUAL MEETING OF STOCKHOLDERS Company Also Provides Update on Exchange Listing SAN DIEGO, CA – July 2, 2013 - Cardium Therapeutics (NYSE MKT: CXM) today reported the voting results of its
July 3, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): July 2, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation)
June 21, 2013	DEFA14A	- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 6, 2013	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Pro
May 28, 2013	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Pro
May 15, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 CARDIUM THERAPEUTICS, INC
May 6, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): April 30, 2013 CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State of incorporation) (Commission file numbe
May 6, 2013	EX-99.1	CARDIUM ANNOUNCES EXCELLAGEN PRESENTATION AT THE SYMPOSIUM ON ADVANCED WOUND CARE SPRING 2013 MEETING EX-99.1 Exhibit 99.1 Investor Contact: Sales and Marketing Contact: Bonnie Ortega Hanna Wagari VP, Corporate Communications VP, Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM ANNOUNCES EXCELLAGEN PRESENTATION AT THE SYMPOSIUM ON ADVANCED WOUND CARE SPRING
May 6, 2013	EX-99.2	CARDIUM ANNOUNCES GENERX PUBLICATION IN MOLECULAR THERAPY EX-99.2 Exhibit 99.2 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES GENERX PUBLICATION IN MOLECULAR THERAPY SAN DIEGO, CA – May 2, 2013 – Cardium Therapeutics (NYSE MKT: CXM) today announced a publication, “Mechanistic, Technical, and Clinical Perspectives in Therapeutic
April 29, 2013	DEF 14A	- DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Pro
April 25, 2013	PRER14A	- PRER14A PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Pro
April 25, 2013	CORRESP	- Response to SEC Comment Letter CARDIUM THERAPEUTICS, INC. 12255 El Camino Real, Suite 250 San Diego, California 92130 April 25, 2013 VIA EDGAR Mr. Jeffrey P. Riedler, Assistant Director U. S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Cardium Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 16, 2013 Fi
April 16, 2013	PRE 14A	- PRE 14A PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Pro
April 11, 2013	EX-99.1	CARDIUM PRESENTS YEAR-END 2012 FINANCIAL RESULTS AND RECENT DEVELOPMENTS EX-99.1 Exhibit 99.1 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM PRESENTS YEAR-END 2012 FINANCIAL RESULTS AND RECENT DEVELOPMENTS SAN DIEGO, CA – April 5, 2013 – Cardium Therapeutics (NYSE MKT: CXM) today presented highlights of financial results for fiscal year ended December 3
April 11, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): April 5, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation
April 5, 2013	EX-21.1	Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Post-Hypothermia Corporation Delaware, USA Tissue Repair Company Delaware, USA To Go Brands, Inc. Delaw Exhibit 21 Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Post-Hypothermia Corporation Delaware, USA Tissue Repair Company Delaware, USA To Go Brands, Inc. Delaware, USA MedPodium Health Sciences, Inc. Delaware, USA
April 5, 2013	EX-99.1	CARDIUM ANNOUNCES $4.0 MILLION PREFERRED STOCK FINANCING AND REPORTS ON EXCHANGE LISTING COMPLIANCE EX-99.1 Exhibit 99.1 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES $4.0 MILLION PREFERRED STOCK FINANCING AND REPORTS ON EXCHANGE LISTING COMPLIANCE SAN DIEGO, CA – April 5, 2013 – Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into a definitive
April 5, 2013	EX-10.3	PLACEMENT AGENCY AGREEMENT April 4, 2013 EX-10.3 Exhibit 10.3 PLACEMENT AGENCY AGREEMENT April 4, 2013 Ladenburg Thalmann & Co. Inc. 4400 Biscayne Blvd 14th Floor Miami, Florida 33137 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Cardium Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $4,012,000 of registered convertible preferred
April 5, 2013	EX-10.1	Securities Purchase Agreement dated April 4, 2013 between the registrant and Sabby Master Volatility Fund for the purchase of Series A Convertible Preferred Stock. EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 4, 2013, between Cardium Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and
April 5, 2013	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 4, 2013 Cardium Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incorporation) (Comm
April 5, 2013	424B5	Up to 4,012 Shares of Series A Convertible Preferred Stock Prospectus Supplement No. 4 Table of Contents Filed Pursuant to Rule 424(b)(5) File No. 333-168693 PROSPECTUS SUPPLEMENT NO. 4 (To Prospectus dated August 27, 2010) Up to 4,012 Shares of Series A Convertible Preferred Stock We are offering and selling up to 4,012 shares of our newly authorized Series A Convertible Preferred Stock, par value $0.0001 per share, at a price of $1,000 per share, direct
April 5, 2013	EX-3.1	Certificate of Designation for Series A Convertible Preferred Stock EX-3.1 Exhibit 3.1 EXHIBIT A CARDIUM THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Christopher J. Reinhard and Tyler M. Dylan-Hyde, do hereby certify that: 1. They are the President and Secretary, respectively, of Cardium Therapeutics, Inc.
April 5, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2012 (Commission file number) CARDIUM THERAP Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation) (IRS Empl
April 1, 2013	NT 10-K	- NT 10-K NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
March 15, 2013	8-K	- FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): March 14, 2013 CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-33635 27-0075787 (State of incorporation) (Commission file numbe
March 15, 2013	EX-99.1	Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARD EX-99.1 Exhibit 99.1 Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM RECEIVES ISO CERTIFICATION FOR EXCELLAGEN SAN DIEGO, CA – March 14, 2013 – Cardium Therapeutics (NYSE MKT: CXM) today announc
February 15, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): February 12, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpora
February 15, 2013	EX-99.1	Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARD EX-99.1 Exhibit 99.1 Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM’S EXCELLAGEN® AWARDED AMERICAN PODIATRIC MEDICAL ASSOCIATION SEAL OF APPROVAL Company Also Announces Addition of a Regional D
February 1, 2013	EX-99.1	CARDIUM ANNOUNCES PRESENTATION AT THE 2013 CELL & GENE THERAPY FORUM New Insights and Discoveries Support Clinical Advancement of Company’s Generx® Angiogenic Therapy for Coronary Artery Disease Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES PRESENTATION AT THE 2013 CELL & GENE THERAPY FORUM New Insights and Discoveries Support Clinical Advancement of Company’s Generx® Angiogenic Therapy for Coronary Artery Disease SAN DIEGO, CA – Janua
February 1, 2013	8-K	Current Report Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): January 29, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporat
January 17, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): January 16, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporat
January 17, 2013	EX-99.1	CARDIUM EXCHANGE LISTING COMPLIANCE PLAN ACCEPTED BY NYSE MKT Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM EXCHANGE LISTING COMPLIANCE PLAN ACCEPTED BY NYSE MKT SAN DIEGO, CA – January 16, 2013 – Cardium Therapeutics (NYSE MKT: CXM) today reported that its exchange listing compliance plan submitted on December 6,
January 7, 2013	EX-99.2	CARDIUM TO PRESENT AT BIOTECH SHOWCASE 2013 INVESTMENT CONFERENCE AND REPORT ON NEW CARDIUM INITIATIVES Press Release Exhibit 99.2 Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM TO PRESENT AT BIOTECH SHOWCASE 2013 INVESTMENT CONFERENCE AND REPORT ON NEW CARDIUM INITIATIVES SAN DIEGO, CA – January 4, 2013 – Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, the Company’s Chairma
January 7, 2013	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): January 3, 2013 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporati
January 7, 2013	EX-99.1	CARDIUM ANNOUNCES SALES AND DISTRIBUTION AGREEMENT WITH ACADEMY MEDICAL TO PROMOTE EXCELLAGEN CLINICAL ADOPTION BY U.S. GOVERNMENT MEDICAL PROVIDERS Press Release Exhibit 99.1 Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES SALES AND DISTRIBUTION AGREEMENT WITH ACADEMY MEDICAL TO PROMOTE EXCELLAGEN CLINICAL ADOPTION BY U.S. GOVERNMENT MEDICAL PROVIDERS SAN DIEGO, CA – January 3, 2013 – Cardium Therapeutics (NYSE MKT: CXM) today announced a dist
December 11, 2012	8-K/A	Financial Statements and Exhibits - AMENDMENT NO. 1 TO FORM 8-K Amendment No. 1 to Form 8-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): SEPTEMBER 28, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified
December 7, 2012	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 3, 2012 Cardium Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incorporation) (C
December 7, 2012	EX-99.1	CARDIUM REPORTS ON NYSE MKT NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM REPORTS ON NYSE MKT NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN SAN DIEGO, CA – December 6, 2012 – Cardium Therapeutics (NYSE MKT: CXM) reported on a communication from staff of its current listing exchang
November 21, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): November 19, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpora
November 21, 2012	EX-99.1	CARDIUM ANNOUNCES PATENT AWARD FOR RIGHTS TO CARDIOVASCULAR GENE THERAPY FOR THE TREATMENT OF HEART DISEASE Resolves Long-standing Competition with Boston Scientific Corporation Over Rights to Cardiovascular Gene Therapy in the U.S. and Europe Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Vice President – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES PATENT AWARD FOR RIGHTS TO CARDIOVASCULAR GENE THERAPY FOR THE TREATMENT OF HEART DISEASE Resolves Long-standing Competition with Boston Scientific Corporation Over Rights to Cardiovascu
November 16, 2012	EX-99.1	CARDIUM ANNOUNCES EXCELLAGEN POSTER PRESENTATONS AT DESERT FOOT 9TH ANNUAL HIGH RISK DIABETIC FOOT CONFERENCE Company Also Announces Excellagen Profiles in Excellence 2012 Article Published in Podiatry Management Press Release of Cardium issued on November 13, 2012 Exhibit 99.1 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES EXCELLAGEN POSTER PRESENTATONS AT DESERT FOOT 9TH ANNUAL HIGH RISK DIABETIC FOOT CONFERENCE Company Also Announces Excellagen Profiles in Excellence 2012 Artic
November 16, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): November 13, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpora
November 16, 2012	EX-99.2	CARDIUM PRESENTS THIRD QUARTER 2012 FINANCIAL RESULTS AND REPORTS ON RECENT DEVELOPMENTS Press Release of Cardium issued on November 14, 2012 Exhibit 99.2 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM PRESENTS THIRD QUARTER 2012 FINANCIAL RESULTS AND REPORTS ON RECENT DEVELOPMENTS SAN DIEGO, CA – November 14, 2012 – Cardium Therapeutics (NYSE MKT: CXM) today presented
November 14, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 CARDIUM THERAPEUTICS,
October 4, 2012	EX-10.1	ASSET PURCHASE AGREEMENT BY AND AMONG TO GO BRANDS, INC. MEDPODIUM HEALTH PRODUCTS, INC., CARDIUM THERAPEUTICS, INC., Owner of Buyer. Dated as of September 28, 2012 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE OF ASSETS 1 1.1 Purchase and Sale Asset Purchase Agreement Exhibit 10.1 ASSET PURCHASE AGREEMENT BY AND AMONG TO GO BRANDS, INC. Seller, MEDPODIUM HEALTH PRODUCTS, INC., Buyer, AND CARDIUM THERAPEUTICS, INC., Owner of Buyer. Dated as of September 28, 2012 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE OF ASSETS 1 1.1 Purchase and Sale of Assets 1 1.2 Excluded Assets 4 1.3 Assumption of Liabilities 4 1.4 Excluded Liabilities 5
October 4, 2012	8-K	Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): September 28, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpor
October 4, 2012	EX-99.1	CARDIUM ANNOUNCES THE ACQUISITION OF TO GO BRANDS Press Release Exhibit 99.1 Press / Investor Contact: Media /Sales Contact: Bonnie Ortega Hanna Wagari VP – Corporate Communications VP – Sales & Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM ANNOUNCES THE ACQUISITION OF TO GO BRANDS SAN DIEGO, CA – October 1, 2012
September 27, 2012	EX-99.2	CARDIUM TO PRESENT AT 2012 NOBLE FINANCIAL LIFE SCIENCES INVESTOR CONFERENCE Press Release Exhibit 99.2 Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM TO PRESENT AT 2012 NOBLE FINANCIAL LIFE SCIENCES INVESTOR CONFERENCE SAN DIEGO, CA – September 24, 2012 – Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will p
September 27, 2012	EX-99.1	CARDIUM ANNOUNCES MEDICAL ADVISORY BOARD TO SUPPORT EXCELLAGEN ADVANCED WOUND CARE PRODUCT Press Release Exhibit 99.1 Investor Contact: Sales and Marketing Contact: Bonnie Ortega Hanna Wagari VP, Corporate Communications VP, Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics Tel: (858) 436-1018 Tel: (858) 436-1042 Email: [email protected] Email: [email protected] CARDIUM ANNOUNCES MEDICAL ADVISORY BOARD TO SUPPORT EXCELLAGEN ADVANCED WOUND CARE PRODU
September 27, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): September 20, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpor
September 19, 2012	SC 13D/A	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. / SABBY MANAGEMENT, LLC - SABBY MANAGEMENT, LLC FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* CARDIUM THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 141916106 (CUSIP Number) Robert Grundstein Sabby Management, LLC 10 Mountainview Road, Suite 205 Upper Saddle River, New Jersey 07458 United States of America Tel. No
September 5, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): August 30, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporati
September 5, 2012	EX-99.1	CARDIUM TO PRESENT AT THE RODMAN & RENSHAW ANNUAL 2012 HEALTHCARE INVESTMENT CONFERENCE Press Release of Cardium Exhibit 99.1 Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM TO PRESENT AT THE RODMAN & RENSHAW ANNUAL 2012 HEALTHCARE INVESTMENT CONFERENCE SAN DIEGO, CA – August 30, 2012 – Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Ch
August 30, 2012	SC 13D	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. / SABBY MANAGEMENT, LLC - SABBY MANAGEMENT, LLC FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CARDIUM THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 141916106 (CUSIP Number) Robert Grundstein Sabby Management, LLC 10 Mountainview Road, Suite 205 Upper Saddle River, New Jersey 07458 United States of America Tel. No.
August 20, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): August 14, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporati
August 20, 2012	EX-99.1	CARDIUM PRESENTS SECOND QUARTER 2012 FINANCIAL RESULTS AND REPORTS ON RECENT DEVELOPMENTS Press Release of Cardium Exhibit 99.1 Press / Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM PRESENTS SECOND QUARTER 2012 FINANCIAL RESULTS AND REPORTS ON RECENT DEVELOPMENTS SAN DIEGO, CA – August 14, 2012 – Cardium Therapeutics (NYSE MKT: CXM) today presented its financial results for th
August 14, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 CARDIUM THERAPEUTICS, INC.
August 7, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): August 1, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporatio
August 7, 2012	EX-99.1	CARDIUM’S EXCELLAGEN® NAMED AS TOP 10 INNOVATION IN PODIATRY Press Release Exhibit 99.1 Press / Investor Contact: Sales/Marketing Contact: Bonnie Ortega Hanna Wagari VP, Corporate Communications VP, Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1005 Email: [email protected] Email: [email protected] CARDIUM’S EXCELLAGEN® NAMED AS TOP 10 INNOVATION IN PODIATRY SAN DIEGO, CA – A
July 31, 2012	EX-99.1	PUBLISHED FINDINGS IN HUMAN GENE THERAPY METHODS JOURNAL DEMONSTRATE CARDIUM’S NEW CATHETER-BASED METHOD SIGNIFICANTLY BOOSTS GENE DELIVERY TO THE HEART PRESS RELEASE Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Vice President – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] PUBLISHED FINDINGS IN HUMAN GENE THERAPY METHODS JOURNAL DEMONSTRATE CARDIUM’S NEW CATHETER-BASED METHOD SIGNIFICANTLY BOOSTS GENE DELIVERY TO THE HEART SAN DIEGO, CA – July 26, 2012 – Cardium Therapeutic
July 31, 2012	8-K	Current Report FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): July 26, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation
June 26, 2012	EX-99.1	CARDIUM ANNOUNCES LAUNCH OF NEW MEDPODIUM NEO-CHILL NUTRA-APP® AT NACDS MARKETPLACE 2012 MedPodium Sponsors Magnolia Howell in Quest to Compete at the 2012 London Summer Olympics Press Release Exhibit 99.1 Media /Sales Contact: Hanna Wagari VP – Sales & Marketing Cardium Therapeutics, Inc. Tel: (858) 436-1042 Email: [email protected] CARDIUM ANNOUNCES LAUNCH OF NEW MEDPODIUM NEO-CHILL NUTRA-APP® AT NACDS MARKETPLACE 2012 MedPodium Sponsors Magnolia Howell in Quest to Compete at the 2012 London Summer Olympics SAN DIEGO, CA – June 19, 2012 – Cardium Therapeutics (NYSE
June 26, 2012	8-K	Current Report Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): June 19, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation
June 15, 2012	EX-99.1	CARDIUM ANNOUNCES PLANS FOR COMMERCIALIZATON OF EXCELLAGEN® IN THE RUSSIAN FEDERATION Press Release Exhibit 99.1 Press / Investor Contact: Sales/Marketing Contact: Bonnie Ortega Hanna Wagari VP, Corporate Communications VP, Sales and Marketing Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1005 Email: [email protected] Email: [email protected] CARDIUM ANNOUNCES PLANS FOR COMMERCIALIZATON OF EXCELLAGEN® IN THE RUSSIAN FED
June 15, 2012	EX-99.2	CARDIUM TO PRESENT AT THE MARCUM MICROCAP CONFERENCE Press Release of Cardium Issued on June 14, 2012 Exhibit 99.2 Investor Contact: Bonnie Ortega VP – Corporate Communications Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM TO PRESENT AT THE MARCUM MICROCAP CONFERENCE SAN DIEGO, CA – June 14, 2012 – Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will p
June 15, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): June 12, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation
June 5, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): May 31, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation)
May 21, 2012	EX-99.4	CARDIUM TO PRESENT AT SACHS ASSOCIATES 2012 SCIENCE, PARTNER, AND INVESTMENT FORUM: GATEWAY FOR THE GLOBAL LIFE SCIENCES PRESS RELEASE Exhibit 99.4 Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM TO PRESENT AT SACHS ASSOCIATES 2012 SCIENCE, PARTNER, AND INVESTMENT FORUM: GATEWAY FOR THE GLOBAL LIFE SCIENCES SAN DIEGO, CA – May 17, 2012 – Cardium Therapeutics (NYSE MKT: CXM) today announced that Christop
May 21, 2012	EX-99.2	CARDIUM ANNOUNCES AGREEMENT WITH UK-BASED ANGEL BIOMEDICAL FOR EXCELLAGEN SUPPLY AND PLANNED EUROPEAN MARKET EXPANSION PRESS RELEASE Exhibit 99.2 Press / Investor Contact: Sales/Marketing Contact: Bonnie Ortega Sarah Dennison Director, Investor/Public Relations Director, Marketing and Sales Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1005 Email: [email protected] Email: [email protected] CARDIUM ANNOUNCES AGREEMENT WITH UK-BASED ANGEL BIOMEDICAL FO
May 21, 2012	EX-99.1	CARDIUM PRESENTS FIRST QUARTER 2012 FINANCIAL RESULTS AND RECENT DEVELOPMENTS PRESS RELEASE Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM PRESENTS FIRST QUARTER 2012 FINANCIAL RESULTS AND RECENT DEVELOPMENTS SAN DIEGO, CA – May 15, 2012 – Cardium Therapeutics (NYSE Amex: CXM) today presented its financial results for the first quarter end
May 21, 2012	8-K	- FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): May 15, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation)
May 21, 2012	EX-99.3	CARDIUM REPORTS NEW CATHETER-BASED METHODS SIGNIFICANTLY BOOST CARDIAC GENE DELIVERY IN LATE-BREAKING PRESENTATION AT 2012 AMERICAN SOCIETY OF GENE & CELL THERAPY MEETING PRESS RELEASE Exhibit 99.3 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM REPORTS NEW CATHETER-BASED METHODS SIGNIFICANTLY BOOST CARDIAC GENE DELIVERY IN LATE-BREAKING PRESENTATION AT 2012 AMERICAN SOCIETY OF GENE & CELL THERAPY MEETING SAN DIEGO, CA – May 16, 2012 – Cardium
May 15, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-33635 CARDIUM THERAPEUTICS, INC
April 24, 2012	DEF 14A	- DEFINITIVE PROXY STATEMENT Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 4, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): March 30, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporatio
April 4, 2012	EX-99.1	CARDIUM ANNOUNCES U.S. MARKET INTRODUCTION OF EXCELLAGEN™ Company also Announces Smith Medical Partners as Logistics Partner for National Distribution of Excellagen™ Press Release Exhibit 99.1 Press / Investor Contact: Sales/Marketing Contact: Bonnie Ortega Sarah Dennison Director, Investor/Public Relations Director, Marketing and Sales Cardium Therapeutics, Inc. Cardium Therapeutics, Inc. Tel: (858) 436-1018 Tel: (858) 436-1005 Email: [email protected] Email: [email protected] CARDIUM ANNOUNCES U.S. MARKET INTRODUCTION OF EXCELLAGEN™ Com
April 4, 2012	EX-99.2	CARDIUM PRESENTS FOURTH QUARTER AND YEAR-END 2011 FINANCIAL RESULTS AND RECENT DEVELOPMENTS Press Release Exhibit 99.2 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM PRESENTS FOURTH QUARTER AND YEAR-END 2011 FINANCIAL RESULTS AND RECENT DEVELOPMENTS SAN DIEGO, CA – March 30, 2012 – Cardium Therapeutics (NYSE AMEX: CXM) today presented highlights of financial results
March 30, 2012	EX-10.33	STRATEGIC PARTNERSHIP AGREEMENT Exhibit 10.33 STRATEGIC PARTNERSHIP AGREEMENT This Strategic Partnership Agreement (the “Agreement”) is made and entered into as of the 20th of December, 2011 (the “Effective Date”), by and between MedPodium Health Products, Inc., a Delaware corporation with offices at 12255 El Camino Real, Suite 250, San Diego, CA 92130, and its parent company MedPodium Health Sciences, Inc., a Delaware corporati
March 30, 2012	EX-21.1	Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Post-Hypothermia Corporation Delaware, USA Tissue Repair Company Delaware, USA Cardium Healthcare, Inc. Subsidiaries of the registrant Exhibit 21 Subsidiaries of Cardium Therapeutics, Inc., a Delaware corporation Name of Subsidiary State or other Jurisdiction of Incorporation or Organization Post-Hypothermia Corporation Delaware, USA Tissue Repair Company Delaware, USA Cardium Healthcare, Inc. Delaware, USA. MedPodium Health Sciences, Inc. Delaware, USA MedPodium Health Products, Inc. Delaware, USA
March 30, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2011 (Commission file number) CARDIUM THERAP Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2011 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporation) (IRS Empl
March 23, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): March 20, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporatio
March 23, 2012	EX-99.1	CARDIUM INITIATES GENERX® PHASE 3 CLINICAL REGISTRATION STUDY Study to Evaluate Generx® (Ad5FGF-4) DNA-based Angiogenic Drug Candidate for the Potential Treatment of Myocardial Ischemia Due to Coronary Artery Disease Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM INITIATES GENERX® PHASE 3 CLINICAL REGISTRATION STUDY Study to Evaluate Generx® (Ad5FGF-4) DNA-based Angiogenic Drug Candidate for the Potential Treatment of Myocardial Ischemia Due to Coronary Artery D
February 21, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): February 16, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorpora
February 21, 2012	EX-99.1	CARDIUM ANNOUNCES CLOSING OF $5.0 MILLION EQUITY FINANCING Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES CLOSING OF $5.0 MILLION EQUITY FINANCING SAN DIEGO, CA – February 16, 2012 – Cardium Therapeutics (NYSE Amex: CXM) today announced that it has completed the previously announced sale of 17,857
February 16, 2012	SC 13G	CRXM / Taxus Cardium Pharmaceuticals Group, Inc. / SABBY MANAGEMENT, LLC - SABBY MANAGEMENT, LLC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2012	EX-10.1	SECURITIES PURCHASE AGREEMENT Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 12, 2012, between Cardium Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS,
February 13, 2012	EX-99.1	CARDIUM ANNOUNCES $5.0 MILLION FINANCING WITH INSTITUTIONAL INVESTORS Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES $5.0 MILLION FINANCING WITH INSTITUTIONAL INVESTORS SAN DIEGO, CA – February 13, 2012 – Cardium Therapeutics (NYSE Amex: CXM) today announced that it has entered into definitive agreements wit
February 13, 2012	EX-10.2	PLACEMENT AGENCY AGREEMENT February 12, 2012 Placement Agent Agreement Exhibit 10.2 PLACEMENT AGENCY AGREEMENT February 12, 2012 Ladenburg Thalmann & Co. Inc. 4400 Biscayne Blvd 14th Floor Miami, Florida 33137 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Cardium Therapeutics, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $5,000,000 of registered
February 13, 2012	424B5	Up to 17,857,143 Shares of Common Stock Prospectus Supplement NO.3 Table of Contents Filed Pursuant to Rule 424(b)(5) File No. 333-168693 PROSPECTUS SUPPLEMENT NO. 3 (To Prospectus dated August 27, 2010) Up to 17,857,143 Shares of Common Stock We are offering and selling up to 17,857,143 shares of our common stock, par value $0.0001 per share, at a price of $0.28 per share, directly to investors pursuant to this prospectus supplement an
February 13, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 12, 2012 Cardium Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33635 27-0075787 (State or Other Jurisdiction of Incorporation) (
February 2, 2012	EX-99.1	CARDIUM PRESENTS NEW GENERX FINDINGS AT 2012 ANNUAL GENE AND CELL THERAPY FORUM New insights Support Generx Angiogenic Therapy Phase 3 Registration Clinical Study for Patients with Coronary Artery Disease Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM PRESENTS NEW GENERX FINDINGS AT 2012 ANNUAL GENE AND CELL THERAPY FORUM New insights Support Generx Angiogenic Therapy Phase 3 Registration Clinical Study for Patients with Coronary Artery Disease SAN D
February 2, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): January 30, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporat
January 10, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): January 5, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporati
January 10, 2012	EX-99.1	CARDIUM ANNOUNCES FIRST INTERNATIONAL MARKETING AND DISTRIBUTION AGREEMENT FOR COMMERCIALIZATION OF EXCELLAGEN™ IN SOUTH KOREA Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM ANNOUNCES FIRST INTERNATIONAL MARKETING AND DISTRIBUTION AGREEMENT FOR COMMERCIALIZATION OF EXCELLAGEN™ IN SOUTH KOREA SAN DIEGO, CA – January 5, 2012 – Cardium Therapeutics (NYSE Amex: CXM) today annou
January 6, 2012	EX-99.1	CARDIUM REGAINS LISTING COMPLIANCE WITH NYSE AMEX Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM REGAINS LISTING COMPLIANCE WITH NYSE AMEX SAN DIEGO, CA – January 6, 2012 – Cardium Therapeutics (NYSE Amex: CXM) today reported that it had received notice from NYSE Regulation that the Company is now
January 6, 2012	8-K	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (Date of earliest event reported): January 5, 2012 001-33635 (Commission file number) CARDIUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0075787 (State of incorporati
January 3, 2012	EX-99.1	CARDIUM REPORTS ON RENEWED COMPLIANCE WITH NYSE AMEX EXCHANGE LISTING GUIDELINES Press Release Exhibit 99.1 Press / Investor Contact: Bonnie Ortega Director, Investor/Public Relations Cardium Therapeutics, Inc. Tel: (858) 436-1018 Email: [email protected] CARDIUM REPORTS ON RENEWED COMPLIANCE WITH NYSE AMEX EXCHANGE LISTING GUIDELINES SAN DIEGO, CA – January 3, 2012 – Cardium Therapeutics (NYSE Amex: CXM) today reported on its exchange listing compliance with NY

CRXM / Gene Biotherapeutics, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)